- Home
- OLP vs VNDA Comparison
OLP vs VNDA Comparison
Compare OLP & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLP | VNDA |
|---|---|---|
| Founded | 1982 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.7M | 411.3M |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | OLP | VNDA |
|---|---|---|
| Price | $22.98 | $6.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $26.75 | $14.90 |
| AVG Volume (30 Days) | 40.1K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | $82,740,000.00 | ★ $216,105,000.00 |
| Revenue This Year | $11.98 | $21.35 |
| Revenue Next Year | $3.71 | $37.40 |
| P/E Ratio | $82.59 | ★ N/A |
| Revenue Growth | 1.02 | ★ 8.72 |
| 52 Week Low | $19.62 | $4.14 |
| 52 Week High | $25.90 | $9.91 |
Technical Indicators
Market Signals| Indicator | OLP | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 38.22 |
| Support Level | $22.36 | $5.73 |
| Resistance Level | $23.61 | $7.76 |
| Average True Range (ATR) | 0.52 | 0.31 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 55.56 | 12.18 |
Price Performance
Historical ComparisonAbout OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.